Intravitreal Fluocinolone Acetonide Implant (ILUVIEN?) for the Treatment of Retinal Conditions. A Review of Clinical Studies

被引：7
|
作者：
Mushtaq, Yusuf [1 ,2 ]
Mushtaq, Maryam M. [3 ]
Gatzioufas, Zisis [4 ,5 ]
Ripa, Matteo [6 ]
Motta, Lorenzo [7 ,9 ]
Panos, Georgios D. [1 ,2 ,8 ]
机构：
[1] Univ Nottingham, Nottingham Univ Hosp NHS Trust, Queens Med Ctr, Dept Ophthalmol, Nottingham, England
[2] Univ Nottingham, Sch Med, Nottingham, England
[3] Luton & Dunstable Univ Hosp NHS Trust, Dept Acute Med, Luton, England
[4] Basel Univ Hosp, Dept Ophthalmol, Basel, Switzerland
[5] Univ Basel, Sch Med, Basel, Switzerland
[6] Fdn Policlin Univ A Gemelli IRCCS, Ophthalmol Unit, Rome, Italy
[7] East Kent Hosp Univ NHS Fdn Trust, William Harvey Hosp, Dept Ophthalmol, Canterbury, Kent, England
[8] Queens Med Ctr, Dept Ophthalmol, Derby Rd, Nottingham NG7 2UH, England
[9] William Harvey Hosp, Dept Ophthalmol, Kennington Rd, Ashford TN24 0LZ, Kent, England
来源：
DRUG DESIGN DEVELOPMENT AND THERAPY | 2023年 / 17卷
关键词：
Iluvien; steroid implant; diabetic macular oedema; intravitreal implant; posterior uveitis; retinal vein occlusion; DIABETIC MACULAR EDEMA; LONG-TERM-BENEFIT; SUSTAINED-DELIVERY; NONINFECTIOUS INTERMEDIATE; AVAILABLE THERAPIES; VITREOUS INSERTS; EFFICACY; SAFETY; INJECTION; EYES;
D O I：
10.2147/DDDT.S403259
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Fluocinolone acetonide (FAc) intravitreal implant (Iluvien (R)) is a corticosteroid implant indicated for the treatment of diabetic macular oedema (DMO) in patients who have previously received conventional treatment without good response, non- infectious posterior uveitis, and as an off-label treatment of the macular oedema secondary to retinal vein occlusion. FAc is a non -biodegradable 0.19 mg intravitreal implant which is designed to release FAc over 3 years at a rate of approximately 0.2 mcg per day. The aim of this review is to describe the special pharmacological properties of Iluvien and display the outcomes of the most important clinical trials and real-world studies regarding its efficacy and safety for the management of the above retinal disorders.
引用
收藏
页码：961 / 975
页数：15
相关论文
共 50 条
  • [21] OZURDEX® (dexamethasone intravitreal implant) vs ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg in non-infectious posterior uveitis (NIPU)
    Abdulla, Didar
    Taylor, Simon
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [22] Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom
    Bailey, C.
    Chakravarthy, U.
    Lotery, A.
    Menon, G.
    Talks, J.
    EYE, 2017, 31 (12) : 1707 - 1715
  • [23] Long-term management of non-ischemic central retinal vein occlusion with fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN®)
    Coelho, Joao
    Pessoa, Bernardete
    Meireles, Angelina
    THERAPEUTIC ADVANCES IN OPHTHALMOLOGY, 2019, 11
  • [24] Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema
    Pessoa, Bernardete
    Coelho, Joao
    Correia, Nuno
    Ferreira, Natalia
    Beirao, Melo
    Meireles, Angelina
    OPHTHALMIC RESEARCH, 2018, 59 (02) : 68 - 75
  • [25] Short Term Results of Fluocinolone Acetonide Intravitreal Implant (Iluvien®) for Diabetic Macular Edema in Highly Treated Eyes
    Dhawlikar, Nisha
    Shah, Sumit P.
    Yarian, David L.
    Prenner, Jonathan L.
    Friedman, Eric S.
    Fine, Howard F.
    Wheatley, H. Matthew
    Roth, Daniel B.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [26] Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom
    C Bailey
    U Chakravarthy
    A Lotery
    G Menon
    J Talks
    Eye, 2017, 31 : 1707 - 1715
  • [27] Migration of a Fluocinolone Acetonide Intravitreal Implant Into the Anterior Chamber
    Li, Angela S.
    Nguyen, Huy V.
    Do, Diana V.
    JAMA OPHTHALMOLOGY, 2020, 138 (10)
  • [28] Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): Final study results from the European IRISS registry study
    Khoramnia, Ramin
    Peto, Tunde
    Taylor, Simon R.
    Castro De Sousa, Joao Paulo
    Hill, Lauren
    Bailey, Clare
    Chakravarthy, Usha
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [29] Effect of Fluocinolone Acetonide Intravitreal Implant on Corneal Astigmatism
    Keppel, Kevin
    Baynes, Kimberly
    Srivastava, Sunil K.
    Goshe, Jeffrey
    See, Craig
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [30] Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema
    Soubrane, G.
    Behar-Cohen, F.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2015, 38 (02): : 159 - 167
12345